Integra LifeSciences Q1 Revenue Rises 2.4%, EPS $0.54; Lifts FY Guidance
IART•Integra LifeSciences reported first-quarter revenue of $391.9 million, up 2.4%, with adjusted EPS of $0.54 versus $0.41 a year earlier. The company reaffirmed revenue guidance and raised its full-year adjusted EPS target to $2.40–$2.50, and CFO Lea Knight will present at the Jefferies Global Healthcare Conference on June 3.
1. Q1 Financial Results and Guidance Update
Integra LifeSciences disclosed first-quarter 2026 revenue of $391.9 million, marking a 2.4% increase year-over-year, with adjusted EPS climbing to $0.54 from $0.41. Management reaffirmed full-year revenue guidance and lifted the adjusted EPS range to $2.40–$2.50, highlighting continued margin expansion prospects.
2. Upcoming Jefferies Conference Presentation
On June 3, CFO Lea Knight will present at the Jefferies Global Healthcare Conference. Investors will gain insights into strategic priorities, progress on neurosurgery and tissue reconstruction portfolios, and updates on clinical pipelines and financial outlook for the remainder of 2026.
